RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 118 filers reported holding RHYTHM PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $217,151,353 | -2.0% | 5,288,635 | +3.5% | 0.04% | -5.1% |
Q1 2024 | $221,485,671 | -4.6% | 5,111,601 | +1.3% | 0.04% | -9.3% |
Q4 2023 | $232,053,526 | +96.1% | 5,047,934 | -2.2% | 0.04% | +72.0% |
Q3 2023 | $118,305,402 | +38.3% | 5,160,541 | -0.5% | 0.02% | +38.9% |
Q2 2023 | $85,517,354 | -9.7% | 5,186,013 | -2.3% | 0.02% | -18.2% |
Q1 2023 | $94,742,942 | -37.5% | 5,310,703 | +2.1% | 0.02% | -40.5% |
Q4 2022 | $151,476,183 | +129322.6% | 5,201,792 | +8.9% | 0.04% | +23.3% |
Q3 2022 | $117,040 | +792.3% | 4,777,178 | +51.2% | 0.03% | +900.0% |
Q2 2022 | $13,116 | -100.0% | 3,160,386 | -5.4% | 0.00% | -62.5% |
Q1 2022 | $38,474,000 | +24.5% | 3,339,750 | +7.9% | 0.01% | +33.3% |
Q4 2021 | $30,904,000 | -18.6% | 3,096,548 | +6.6% | 0.01% | -25.0% |
Q3 2021 | $37,943,000 | +81.4% | 2,905,319 | +172.0% | 0.01% | +60.0% |
Q2 2021 | $20,915,000 | +49.2% | 1,068,211 | +62.1% | 0.01% | +25.0% |
Q1 2021 | $14,021,000 | +799.9% | 659,154 | +1157.6% | 0.00% | – |
Q4 2020 | $1,558,000 | +27.8% | 52,412 | -6.9% | 0.00% | – |
Q3 2020 | $1,219,000 | +65.2% | 56,268 | +70.1% | 0.00% | – |
Q2 2020 | $738,000 | -6.6% | 33,073 | -36.3% | 0.00% | – |
Q1 2020 | $790,000 | -46.9% | 51,914 | -19.9% | 0.00% | – |
Q4 2019 | $1,489,000 | +32.9% | 64,841 | +25.0% | 0.00% | – |
Q3 2019 | $1,120,000 | -8.9% | 51,892 | -7.1% | 0.00% | – |
Q2 2019 | $1,229,000 | -4.5% | 55,844 | +18.9% | 0.00% | – |
Q1 2019 | $1,287,000 | +139.2% | 46,966 | +134.5% | 0.00% | – |
Q4 2018 | $538,000 | +76.4% | 20,031 | +91.3% | 0.00% | – |
Q3 2018 | $305,000 | +29.8% | 10,470 | +39.3% | 0.00% | – |
Q2 2018 | $235,000 | – | 7,518 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 735,000 | $13,112,400 | 3.93% |
NEA Management Company, LLC | 2,909,956 | $51,913,615 | 3.59% |
Frazier Life Sciences Management, L.P. | 2,164,739 | $38,618,944 | 2.80% |
RA Capital Management | 5,516,067 | $98,406,635 | 2.23% |
Samsara BioCapital, LLC | 345,293 | $6,160,027 | 1.27% |
Rock Springs Capital Management LP | 1,597,123 | $28,492,674 | 0.68% |
Baker Brothers Advisors | 6,498,267 | $115,929,083 | 0.63% |
HighVista Strategies LLC | 35,478 | $632,928 | 0.52% |
Nan Fung Group Holdings Ltd | 32,520 | $580,157 | 0.40% |
GREAT POINT PARTNERS LLC | 97,544 | $1,740,185 | 0.34% |